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Introduction
CD8 T cell response comprises effector and memory
T cells. Effector CD8 T cells become terminally differen-
tiated and are eliminated by apoptosis. Memory CD8 T
cells encompass central (TCM) and effector memory T
cells (TEM). TCM display a higher proliferative ability,
express a higher level of CD62L and are superior in
their protection against viral and bacterial challenges
and mediation of anti-tumor immunity when compared
to TEM. The differentiation of CD8 T cell is thought to
be coordinated by the PI3K/Akt pathway.
Methods
The effect of in vitro Akt inhibition using the pan Akt
inhibitors MK-2206 and AZD5363 on the differentiation
and proliferation of CD8 T cells was examined. Cell
proliferation, expansion, cytokine production and phe-
notype were assessed in antigen specific CD8 T cells.
Results
We found that the inhibition of Akt leads to a signifi-
cant enhancement of the proliferative potential of CD8
T cells, and to prolongation of their survival upon TCR
re-stimulation. Furthermore, we found that Akt inhibi-
tion leads to increase in IL-2 secretion, a marker of cells
with high proliferative ability. We further identified that
Akt inhibition preserved the TCM phenotype by conser-
ving a higher percentage of (CD44HI CD62LHI) expres-
sing T cells. These cells also displayed a higher level of
CD127 and a lower level of the exhaustion marker
KLRG-1 reflecting their increased expansion ability and
longevity due to Akt inhibition. Additionally, we found
that Akt inhibition also resulted in the preservation of a
significantly higher percentage of naïve CD8 T cells
(CD44LO CD62LHI) when compared to the non-treated
cells.
Conclusion
Here, we show that Akt inhibition preserves the central
memory phenotype of CD8 T cells thus enhancing their
proliferation, survival and cytokine production. Further-
more, Akt inhibition results in the conservation of a
reservoir of naïve CD8 T cells. Both naïve and TCM
CD8 T cells are superior mediators of anti-tumor
immunity when compared to effector or TEM cells.
These findings strongly suggest the utility of using Akt
inhibitors to modulate the immune response as part of
cancer immune therapy.
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